Ekarpen, BBK lead €9m round for Oncomatryx

The company's shareholders, as well as several Basque and Galician family offices, also took part in the round.

The capital raised will enable its drug OMTX705 to begin a phase-I clinical trial by Q2 2020 in people suffering from pancreatic and lung cancer. 

Company
Established in 2009 and based in Derio, Basque Country, Oncomatryx specialises in developing novel precision cancer drugs able to target proteins located in the tumour stroma. The company's OMTX705 and OMTX503 drugs attack stromal cells located in the tumour microenvironment in order to block growth, metastasis, immune suppression and drug resistance.

People
Oncomatryx – Laurano Simon (CEO).

Advisers
Equity – GBP Legal (legal).
Company – Cuatrecasas (legal); Norgestion (corporate finance); Deloitte (financial due diligence).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Southern Europe
• Healthcare
• Venture
• Spain